4151 Stock Overview
Engages in the research, development, manufacturing, marketing, and import/export of pharmaceuticals for oncology, nephrology, central nervous system, and immunology therapeutic areas in Japan, the United States, rest of the Americas, Europe, Asia, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 5/6 |
Rewards
Risk Analysis
No risks detected for 4151 from our risk checks.
Kyowa Kirin Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥2,525.50 |
| 52 Week High | JP¥3,350.00 |
| 52 Week Low | JP¥2,266.50 |
| Beta | 0.24 |
| 11 Month Change | -4.30% |
| 3 Month Change | -20.03% |
| 1 Year Change | 2.58% |
| 33 Year Change | -25.17% |
| 5 Year Change | 10.43% |
| Change since IPO | 91.33% |
Recent News & Updates
What Kyowa Kirin Co., Ltd.'s (TSE:4151) P/E Is Not Telling You
Oct 22
Kyowa Kirin Co., Ltd. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Aug 03Recent updates
What Kyowa Kirin Co., Ltd.'s (TSE:4151) P/E Is Not Telling You
Oct 22Kyowa Kirin Co., Ltd. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Aug 03Here's Why Kyowa Kirin (TSE:4151) Has Caught The Eye Of Investors
Jul 30Kyowa Kirin Co., Ltd.'s (TSE:4151) Share Price Could Signal Some Risk
Jul 11Kyowa Kirin (TSE:4151) Is Due To Pay A Dividend Of ¥29.00
Jun 19Are Investors Undervaluing Kyowa Kirin Co., Ltd. (TSE:4151) By 35%?
Jun 14Earnings Miss: Kyowa Kirin Co., Ltd. Missed EPS By 5.6% And Analysts Are Revising Their Forecasts
May 09Kyowa Kirin (TSE:4151) Is Due To Pay A Dividend Of ¥29.00
Apr 25Kyowa Kirin's (TSE:4151) Dividend Will Be ¥29.00
Apr 11Here's Why We Think Kyowa Kirin (TSE:4151) Is Well Worth Watching
Mar 19Kyowa Kirin Co., Ltd.'s (TSE:4151) 26% Price Boost Is Out Of Tune With Earnings
Feb 27Shareholder Returns
| 4151 | JP Pharmaceuticals | JP Market | |
|---|---|---|---|
| 7D | -1.6% | -6.0% | -1.2% |
| 1Y | 2.6% | 10.4% | 12.3% |
Return vs Industry: 4151 underperformed the JP Pharmaceuticals industry which returned 10.4% over the past year.
Return vs Market: 4151 underperformed the JP Market which returned 12.3% over the past year.
Price Volatility
| 4151 volatility | |
|---|---|
| 4151 Average Weekly Movement | 4.7% |
| Pharmaceuticals Industry Average Movement | 3.6% |
| Market Average Movement | 3.8% |
| 10% most volatile stocks in JP Market | 7.7% |
| 10% least volatile stocks in JP Market | 2.1% |
Stable Share Price: 4151 has not had significant price volatility in the past 3 months compared to the JP market.
Volatility Over Time: 4151's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1949 | 5,974 | Masashi Miyamoto | www.kyowakirin.com |
Kyowa Kirin Co., Ltd. engages in the research, development, manufacturing, marketing, and import/export of pharmaceuticals for oncology, nephrology, central nervous system, and immunology therapeutic areas in Japan, the United States, rest of the Americas, Europe, Asia, and internationally. Its products include ALLELOCK, an antihistamine agent for patients with various types of allergies; CONIEL, a calcium channel blocker for hypertension and angina pectoris; Crysvita, a recombinant human monoclonal IgG1 antibody against the phosphaturic hormone fibroblast growth factor 23; ESPO, a glycoprotein and human erythropoietin; NESP, an erythropoiesis stimulating agent; and GRAN, a human colony-stimulating factor. The company also develops GRAN /Peglasta/Neulasta for chemotherapy-induced febrile neutropenia; LUMICEF, a biological treatment for moderate to severe plaque psoriasis; Moventig, a mu-opioid receptor antagonist for the treatment of opioid induced constipation; Nouriast/ Nourianz, an adenosine receptor antagonist for Parkinson’s disease; and ORKEDIA, an oral calcimimetics agent.
Kyowa Kirin Co., Ltd. Fundamentals Summary
| 4151 fundamental statistics | |
|---|---|
| Market cap | JP¥1.30t |
| Earnings (TTM) | JP¥83.54b |
| Revenue (TTM) | JP¥498.98b |
15.4x
P/E Ratio2.6x
P/S RatioIs 4151 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4151 income statement (TTM) | |
|---|---|
| Revenue | JP¥498.98b |
| Cost of Revenue | JP¥128.24b |
| Gross Profit | JP¥370.74b |
| Other Expenses | JP¥287.20b |
| Earnings | JP¥83.54b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 06, 2025
| Earnings per share (EPS) | 164.12 |
| Gross Margin | 74.30% |
| Net Profit Margin | 16.74% |
| Debt/Equity Ratio | 0% |
How did 4151 perform over the long term?
See historical performance and comparisonDividends
2.3%
Current Dividend Yield37%
Payout RatioDoes 4151 pay a reliable dividends?
See 4151 dividend history and benchmarks| Kyowa Kirin dividend dates | |
|---|---|
| Ex Dividend Date | Dec 27 2024 |
| Dividend Pay Date | Mar 25 2025 |
| Days until Ex dividend | 37 days |
| Days until Dividend pay date | 125 days |
Does 4151 pay a reliable dividends?
See 4151 dividend history and benchmarks